Cellectis S.A. (CLLS) Form 6-K — Oct 28, 2026
Cellectis presented expanded preclinical data for .HEAL-101, its in vivo base editing candidate targeting APOC3 for severe hypertriglyceridemia, at ESGCT 2026 in Hamburg. A single intravenous dose achieved up to 70% editing of human APOC3 in a humanized liver mouse model and reduced triglycerides by 75% ± 11% in a disease model, with liver-restricted activity. In vitro, .HEAL-101 achieved roughly 90% APOC3 editing in human hepatic cells without DNA double strand breaks. The company plans to initiate a Phase 1 investigator-initiated trial in China with preliminary clinical data expected in the second half of 2027.
Key figures
- Apoc3 reduction
- 67% ± 12%
- Phase1 data timing
- second half of 2027
- In vitro editing rate
- approximately 90%
- Triglyceride reduction
- 75% ± 11%
- In vivo editing rate max
- 70%
- In vivo editing rate mean
- approximately 65%
- Triglyceride reduction single dose headline
- 76% triglyceride reduction after a single dose in murine disease model
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.